Eryilmaz, Melek KarakurtKaraagac, Mustafa2024-02-232024-02-2320191078-15521477-092Xhttps://doi.org/10.1177/1078155218818250https://hdl.handle.net/20.500.12452/14418Abiraterone is an oral inhibitor of cytochrome P450 (17alpha)-hydroxylase/17,20 lyase (CYP17) complex critical to androgen production. Abiraterone in combination with prednisone is currently FDA approved for use in men with metastatic castration-resistant prostate cancer, both in the pre- and post-chemotherapy settings. This article discusses the treatment with abiraterone in a patient with metastatic castration-resistant prostate cancer on hemodialysis.eninfo:eu-repo/semantics/closedAccessAbirateroneMetastatic Castration-Resistant Prostate CancerHemodialysisArticle25820312034316944962-s2.0-85074625126Q3WOS:000494855400030Q410.1177/1078155218818250